Jeanne Wei
Concepts (353)
Concept scores are derived automatically based on a person's publications. Keywords in the their attributed publications are matched to keywords from the National Library of Medicine's controlled vocabulary thesaurus, MeSH (Medical Subject Headings). The strength of a person's concept scores is based not only on the number of corresponding publications, but also how relevant the concepts are to the overall topics of the publications, how long ago the publications were written, whether the person was the first or senior author, and how many other people have written about the topic.Concepts cannot be directly edited. You can help ensure your concepts are accurate by making sure your attributed publications are correct and up-to-date. We recommend checking over your attributed publications list every three to four months.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Serum Response Factor | 12 | 2025 | 43 | 5.110 |
Why?
| | Transcription Factors | 9 | 2024 | 566 | 2.660 |
Why?
| | Lipopolysaccharides | 3 | 2025 | 206 | 2.390 |
Why?
| | Doxorubicin | 7 | 2024 | 241 | 2.150 |
Why?
| | Porphyromonas gingivalis | 3 | 2025 | 17 | 2.010 |
Why?
| | Myocardium | 14 | 2024 | 453 | 1.920 |
Why?
| | MicroRNAs | 5 | 2025 | 387 | 1.730 |
Why?
| | Delirium | 2 | 2023 | 52 | 1.570 |
Why?
| | Aging | 10 | 2016 | 701 | 1.430 |
Why?
| | Health Literacy | 2 | 2023 | 132 | 1.410 |
Why?
| | Alzheimer Disease | 5 | 2025 | 332 | 1.390 |
Why?
| | Alternative Splicing | 3 | 2025 | 62 | 1.380 |
Why?
| | Actins | 3 | 2022 | 115 | 1.330 |
Why?
| | Amino Acids, Essential | 4 | 2024 | 133 | 1.220 |
Why?
| | Mitochondria | 8 | 2025 | 430 | 1.060 |
Why?
| | Transcriptome | 4 | 2025 | 370 | 1.060 |
Why?
| | Microglia | 2 | 2025 | 113 | 1.030 |
Why?
| | Gene Expression Regulation | 12 | 2016 | 990 | 1.010 |
Why?
| | Heart | 6 | 2016 | 345 | 0.990 |
Why?
| | Accidental Falls | 3 | 2022 | 105 | 0.980 |
Why?
| | Aged | 30 | 2025 | 10121 | 0.960 |
Why?
| | Caspases, Initiator | 1 | 2025 | 12 | 0.960 |
Why?
| | Mice | 17 | 2024 | 5949 | 0.930 |
Why?
| | Anthracyclines | 1 | 2024 | 32 | 0.900 |
Why?
| | Inflammasomes | 1 | 2025 | 66 | 0.900 |
Why?
| | Heart Failure | 6 | 2025 | 565 | 0.890 |
Why?
| | Heart Diseases | 2 | 2025 | 216 | 0.880 |
Why?
| | Paraffin Embedding | 1 | 2024 | 52 | 0.880 |
Why?
| | Formaldehyde | 1 | 2024 | 51 | 0.880 |
Why?
| | Valine | 1 | 2024 | 57 | 0.850 |
Why?
| | Sequence Analysis, RNA | 1 | 2024 | 100 | 0.840 |
Why?
| | Dietary Supplements | 4 | 2024 | 465 | 0.840 |
Why?
| | Oxidative Stress | 5 | 2025 | 807 | 0.840 |
Why?
| | Amino Acids, Branched-Chain | 1 | 2024 | 43 | 0.830 |
Why?
| | Neutrophils | 1 | 2024 | 147 | 0.830 |
Why?
| | Humans | 53 | 2025 | 52483 | 0.820 |
Why?
| | Glucose | 2 | 2017 | 355 | 0.810 |
Why?
| | Cell Line | 7 | 2025 | 1030 | 0.720 |
Why?
| | Proteomics | 1 | 2024 | 329 | 0.720 |
Why?
| | Physical Therapists | 1 | 2021 | 11 | 0.710 |
Why?
| | Breast Neoplasms | 5 | 2024 | 1212 | 0.710 |
Why?
| | Sirtuins | 1 | 2021 | 11 | 0.710 |
Why?
| | Animals | 20 | 2024 | 13505 | 0.690 |
Why?
| | Geriatrics | 4 | 2019 | 47 | 0.660 |
Why?
| | Gene Expression Profiling | 4 | 2025 | 1105 | 0.660 |
Why?
| | Genetic Variation | 1 | 2021 | 230 | 0.640 |
Why?
| | Primary Health Care | 2 | 2014 | 376 | 0.630 |
Why?
| | Histones | 2 | 2022 | 314 | 0.610 |
Why?
| | RNA, Messenger | 7 | 2021 | 1132 | 0.580 |
Why?
| | Sirtuin 2 | 1 | 2017 | 11 | 0.570 |
Why?
| | Cytoskeletal Proteins | 1 | 2017 | 48 | 0.530 |
Why?
| | Dementia | 2 | 2012 | 134 | 0.530 |
Why?
| | Chronic Disease | 2 | 2025 | 586 | 0.520 |
Why?
| | Mitochondria, Heart | 1 | 2016 | 37 | 0.510 |
Why?
| | Gastrostomy | 2 | 2014 | 58 | 0.500 |
Why?
| | Protein Isoforms | 3 | 2025 | 123 | 0.480 |
Why?
| | Oxygen Consumption | 1 | 2015 | 198 | 0.450 |
Why?
| | Metformin | 1 | 2015 | 76 | 0.450 |
Why?
| | Hypoglycemic Agents | 1 | 2015 | 211 | 0.420 |
Why?
| | Physicians, Primary Care | 1 | 2014 | 46 | 0.420 |
Why?
| | beta-Galactosidase | 1 | 2013 | 33 | 0.410 |
Why?
| | Exons | 2 | 2025 | 102 | 0.410 |
Why?
| | Eating | 2 | 2024 | 159 | 0.400 |
Why?
| | Nitric Oxide Synthase Type III | 1 | 2013 | 78 | 0.400 |
Why?
| | Blood Glucose | 1 | 2015 | 473 | 0.400 |
Why?
| | Hospitalization | 3 | 2018 | 736 | 0.390 |
Why?
| | Antibiotics, Antineoplastic | 3 | 2017 | 80 | 0.390 |
Why?
| | Endoscopy, Gastrointestinal | 1 | 2012 | 76 | 0.380 |
Why?
| | Aged, 80 and over | 13 | 2021 | 3392 | 0.380 |
Why?
| | Health Services for the Aged | 1 | 2012 | 31 | 0.380 |
Why?
| | Female | 26 | 2025 | 28171 | 0.380 |
Why?
| | Malnutrition | 1 | 2012 | 90 | 0.360 |
Why?
| | Nitric Oxide | 1 | 2013 | 249 | 0.360 |
Why?
| | Cardiomegaly | 1 | 2011 | 38 | 0.350 |
Why?
| | Quality Improvement | 2 | 2023 | 226 | 0.350 |
Why?
| | Rats | 5 | 2024 | 3220 | 0.350 |
Why?
| | Patient Discharge | 2 | 2013 | 330 | 0.350 |
Why?
| | Longevity | 2 | 2010 | 85 | 0.350 |
Why?
| | Signal Transduction | 4 | 2024 | 1671 | 0.350 |
Why?
| | Caregivers | 2 | 2023 | 240 | 0.340 |
Why?
| | Male | 19 | 2025 | 26761 | 0.340 |
Why?
| | Education, Medical, Graduate | 1 | 2012 | 219 | 0.320 |
Why?
| | Amino Acid Sequence | 5 | 2011 | 578 | 0.320 |
Why?
| | Collagen | 1 | 2010 | 211 | 0.310 |
Why?
| | Adult | 9 | 2025 | 14161 | 0.310 |
Why?
| | Endocarditis, Bacterial | 1 | 2009 | 43 | 0.300 |
Why?
| | NADH Dehydrogenase | 1 | 2008 | 7 | 0.290 |
Why?
| | Anabolic Agents | 2 | 2019 | 44 | 0.290 |
Why?
| | Electron Transport Complex I | 1 | 2008 | 21 | 0.290 |
Why?
| | Mice, Transgenic | 4 | 2014 | 552 | 0.290 |
Why?
| | Promoter Regions, Genetic | 4 | 2017 | 467 | 0.280 |
Why?
| | Protein Structure, Tertiary | 2 | 2021 | 242 | 0.280 |
Why?
| | Ventricular Pressure | 1 | 2006 | 16 | 0.270 |
Why?
| | Insulin-Like Growth Factor I | 3 | 2016 | 139 | 0.270 |
Why?
| | Isoproterenol | 1 | 2006 | 55 | 0.270 |
Why?
| | Trans-Activators | 3 | 2016 | 135 | 0.250 |
Why?
| | Drug Therapy | 1 | 2006 | 44 | 0.250 |
Why?
| | Nutritional Physiological Phenomena | 1 | 2006 | 22 | 0.250 |
Why?
| | Cachexia | 1 | 2006 | 27 | 0.250 |
Why?
| | Nuclear Proteins | 3 | 2016 | 245 | 0.240 |
Why?
| | Cells, Cultured | 4 | 2015 | 1567 | 0.240 |
Why?
| | Molecular Sequence Data | 4 | 2008 | 778 | 0.240 |
Why?
| | Residence Characteristics | 1 | 2006 | 159 | 0.240 |
Why?
| | Self Care | 1 | 2006 | 138 | 0.230 |
Why?
| | Micronesia | 1 | 2025 | 112 | 0.230 |
Why?
| | Cognition Disorders | 1 | 2006 | 196 | 0.230 |
Why?
| | Amyloid beta-Peptides | 1 | 2025 | 66 | 0.230 |
Why?
| | GPI-Linked Proteins | 1 | 2024 | 32 | 0.230 |
Why?
| | Interleukin-1beta | 1 | 2025 | 86 | 0.230 |
Why?
| | Lysine | 2 | 2022 | 89 | 0.220 |
Why?
| | Independent Living | 2 | 2021 | 46 | 0.220 |
Why?
| | Cell Adhesion Molecules | 1 | 2024 | 86 | 0.220 |
Why?
| | Matrix Metalloproteinase 9 | 1 | 2024 | 87 | 0.220 |
Why?
| | Tissue Fixation | 1 | 2024 | 36 | 0.220 |
Why?
| | Human Umbilical Vein Endothelial Cells | 2 | 2016 | 99 | 0.220 |
Why?
| | Interleukin-18 | 1 | 2024 | 27 | 0.220 |
Why?
| | Isoleucine | 1 | 2024 | 26 | 0.220 |
Why?
| | Middle Aged | 9 | 2025 | 13028 | 0.220 |
Why?
| | RNA, Ribosomal, 16S | 1 | 2024 | 118 | 0.210 |
Why?
| | Human Growth Hormone | 2 | 2017 | 50 | 0.210 |
Why?
| | Proteins | 1 | 2006 | 348 | 0.210 |
Why?
| | Leucine | 1 | 2024 | 114 | 0.210 |
Why?
| | Lewy Body Disease | 1 | 2023 | 5 | 0.210 |
Why?
| | Antigens, CD | 1 | 2024 | 218 | 0.210 |
Why?
| | Reactive Oxygen Species | 1 | 2025 | 421 | 0.200 |
Why?
| | Ternary Complex Factors | 1 | 2022 | 4 | 0.200 |
Why?
| | Cell Size | 2 | 2014 | 45 | 0.200 |
Why?
| | Anilides | 1 | 2022 | 19 | 0.200 |
Why?
| | Estrogens, Conjugated (USP) | 1 | 2002 | 3 | 0.200 |
Why?
| | Blood Proteins | 1 | 2023 | 85 | 0.200 |
Why?
| | Benzamides | 1 | 2022 | 50 | 0.200 |
Why?
| | Mice, Inbred C57BL | 4 | 2016 | 1884 | 0.200 |
Why?
| | Base Sequence | 2 | 2017 | 640 | 0.190 |
Why?
| | Ambulatory Care Facilities | 1 | 2023 | 124 | 0.190 |
Why?
| | NIH 3T3 Cells | 3 | 2008 | 51 | 0.190 |
Why?
| | Neurons | 1 | 2025 | 418 | 0.190 |
Why?
| | Adenosine Triphosphate | 1 | 2022 | 205 | 0.180 |
Why?
| | Genome | 2 | 2021 | 62 | 0.180 |
Why?
| | Diabetes Mellitus | 1 | 2025 | 316 | 0.180 |
Why?
| | Cues | 1 | 2021 | 52 | 0.180 |
Why?
| | Age Factors | 5 | 2010 | 1132 | 0.180 |
Why?
| | Up-Regulation | 2 | 2014 | 454 | 0.180 |
Why?
| | Cardiovascular Diseases | 2 | 2021 | 490 | 0.180 |
Why?
| | Cytokines | 1 | 2024 | 623 | 0.180 |
Why?
| | Genetic Loci | 1 | 2021 | 49 | 0.180 |
Why?
| | Animals, Newborn | 2 | 2014 | 362 | 0.170 |
Why?
| | Zinc | 1 | 2021 | 56 | 0.170 |
Why?
| | Rats, Sprague-Dawley | 1 | 2024 | 1563 | 0.170 |
Why?
| | Focus Groups | 1 | 2021 | 196 | 0.160 |
Why?
| | Cell Line, Tumor | 1 | 2024 | 1470 | 0.160 |
Why?
| | United States | 5 | 2019 | 5192 | 0.160 |
Why?
| | Ventricular Function, Left | 2 | 2017 | 172 | 0.160 |
Why?
| | Arkansas | 1 | 2025 | 2028 | 0.160 |
Why?
| | Food, Formulated | 1 | 2019 | 42 | 0.160 |
Why?
| | Conserved Sequence | 2 | 2011 | 53 | 0.150 |
Why?
| | Blood | 1 | 2017 | 26 | 0.140 |
Why?
| | Culture Media | 1 | 2017 | 98 | 0.140 |
Why?
| | Chemokines | 1 | 2017 | 79 | 0.140 |
Why?
| | Tissue Distribution | 3 | 2008 | 171 | 0.140 |
Why?
| | Down Syndrome | 1 | 2018 | 93 | 0.130 |
Why?
| | Cerebrovascular Disorders | 2 | 2018 | 48 | 0.130 |
Why?
| | Neocortex | 1 | 2016 | 7 | 0.130 |
Why?
| | Stroke Volume | 1 | 2017 | 155 | 0.130 |
Why?
| | Homeostasis | 1 | 2017 | 201 | 0.130 |
Why?
| | Cell Culture Techniques | 1 | 2017 | 102 | 0.130 |
Why?
| | Dietary Proteins | 1 | 2019 | 252 | 0.130 |
Why?
| | Comorbidity | 2 | 2012 | 625 | 0.130 |
Why?
| | Transfection | 1 | 2017 | 357 | 0.130 |
Why?
| | Biomedical Research | 1 | 2019 | 256 | 0.130 |
Why?
| | Blotting, Western | 3 | 2006 | 590 | 0.120 |
Why?
| | cdc42 GTP-Binding Protein | 1 | 2015 | 11 | 0.120 |
Why?
| | AMP-Activated Protein Kinases | 1 | 2015 | 31 | 0.120 |
Why?
| | Aorta | 1 | 2016 | 165 | 0.120 |
Why?
| | Enzyme Activation | 1 | 2015 | 270 | 0.120 |
Why?
| | Transcription, Genetic | 2 | 2016 | 378 | 0.120 |
Why?
| | Prodromal Symptoms | 1 | 2014 | 9 | 0.120 |
Why?
| | Protein Kinases | 1 | 2015 | 72 | 0.120 |
Why?
| | Cell Death | 1 | 2015 | 177 | 0.110 |
Why?
| | Double-Blind Method | 4 | 2021 | 713 | 0.110 |
Why?
| | Actin Cytoskeleton | 1 | 2014 | 22 | 0.110 |
Why?
| | Hippocampus | 1 | 2016 | 201 | 0.110 |
Why?
| | Gastroscopy | 1 | 2014 | 21 | 0.110 |
Why?
| | Protein Binding | 2 | 2008 | 667 | 0.110 |
Why?
| | Hospital Mortality | 3 | 2018 | 435 | 0.110 |
Why?
| | Down-Regulation | 2 | 2016 | 346 | 0.110 |
Why?
| | Coronary Disease | 1 | 2014 | 152 | 0.110 |
Why?
| | Survival Analysis | 3 | 2013 | 673 | 0.100 |
Why?
| | Models, Biological | 2 | 2008 | 735 | 0.100 |
Why?
| | Retrospective Studies | 4 | 2018 | 6607 | 0.100 |
Why?
| | Pneumonia, Aspiration | 1 | 2012 | 13 | 0.100 |
Why?
| | Eukaryotic Initiation Factors | 1 | 2012 | 5 | 0.100 |
Why?
| | Argonaute Proteins | 1 | 2012 | 12 | 0.100 |
Why?
| | Multigene Family | 1 | 2012 | 48 | 0.100 |
Why?
| | Adiponectin | 1 | 2012 | 46 | 0.100 |
Why?
| | Cardiopulmonary Resuscitation | 1 | 2013 | 140 | 0.090 |
Why?
| | Enteral Nutrition | 1 | 2012 | 154 | 0.090 |
Why?
| | Gene Expression | 3 | 2016 | 618 | 0.090 |
Why?
| | Deglutition Disorders | 1 | 2012 | 79 | 0.090 |
Why?
| | Endoplasmic Reticulum | 1 | 2012 | 111 | 0.090 |
Why?
| | Forecasting | 1 | 2012 | 154 | 0.090 |
Why?
| | Adipocytes | 1 | 2012 | 132 | 0.090 |
Why?
| | Hypertension | 1 | 2016 | 565 | 0.090 |
Why?
| | Length of Stay | 2 | 2018 | 663 | 0.090 |
Why?
| | Career Choice | 1 | 2012 | 116 | 0.090 |
Why?
| | Algorithms | 1 | 2014 | 672 | 0.090 |
Why?
| | Time Factors | 4 | 2014 | 2968 | 0.090 |
Why?
| | Health Services Needs and Demand | 1 | 2012 | 159 | 0.090 |
Why?
| | Mice, Inbred Strains | 1 | 2010 | 163 | 0.080 |
Why?
| | Diagnosis, Differential | 1 | 2014 | 1046 | 0.080 |
Why?
| | Extracorporeal Membrane Oxygenation | 1 | 2013 | 295 | 0.080 |
Why?
| | Organ Size | 1 | 2010 | 228 | 0.080 |
Why?
| | Cell Nucleus | 1 | 2010 | 187 | 0.080 |
Why?
| | Dose-Response Relationship, Drug | 1 | 2013 | 1378 | 0.080 |
Why?
| | Longitudinal Studies | 2 | 2014 | 747 | 0.080 |
Why?
| | Paclitaxel | 1 | 2009 | 89 | 0.080 |
Why?
| | Cell Proliferation | 1 | 2013 | 1023 | 0.080 |
Why?
| | Cardiovascular Agents | 1 | 2009 | 59 | 0.080 |
Why?
| | Curriculum | 1 | 2012 | 398 | 0.080 |
Why?
| | Drug-Eluting Stents | 1 | 2009 | 94 | 0.070 |
Why?
| | Cardiology | 1 | 2010 | 97 | 0.070 |
Why?
| | Health Status | 2 | 2009 | 294 | 0.070 |
Why?
| | Piperidines | 1 | 2009 | 97 | 0.070 |
Why?
| | NAD | 1 | 2008 | 45 | 0.070 |
Why?
| | Pyrazoles | 1 | 2009 | 114 | 0.070 |
Why?
| | Protein Subunits | 1 | 2008 | 79 | 0.070 |
Why?
| | Stereotyping | 1 | 2008 | 32 | 0.070 |
Why?
| | Angioplasty, Balloon, Coronary | 1 | 2009 | 136 | 0.070 |
Why?
| | Inflammation | 1 | 2012 | 641 | 0.070 |
Why?
| | Serum Response Element | 1 | 2007 | 4 | 0.070 |
Why?
| | Codon, Nonsense | 1 | 2007 | 28 | 0.070 |
Why?
| | Reproducibility of Results | 2 | 2012 | 1229 | 0.070 |
Why?
| | Placebos | 2 | 2009 | 85 | 0.070 |
Why?
| | HeLa Cells | 1 | 2008 | 265 | 0.070 |
Why?
| | Models, Genetic | 1 | 2007 | 169 | 0.070 |
Why?
| | Myocytes, Cardiac | 1 | 2008 | 129 | 0.070 |
Why?
| | Zinc Fingers | 1 | 2006 | 23 | 0.060 |
Why?
| | Logistic Models | 1 | 2009 | 925 | 0.060 |
Why?
| | Heart Rate | 1 | 2008 | 318 | 0.060 |
Why?
| | Sequence Alignment | 1 | 2006 | 125 | 0.060 |
Why?
| | Organ Specificity | 1 | 2006 | 115 | 0.060 |
Why?
| | Treatment Outcome | 4 | 2018 | 5422 | 0.060 |
Why?
| | Science | 1 | 2005 | 20 | 0.060 |
Why?
| | Stress, Psychological | 1 | 2008 | 273 | 0.060 |
Why?
| | Reverse Transcriptase Polymerase Chain Reaction | 1 | 2006 | 582 | 0.060 |
Why?
| | Binding Sites | 1 | 2006 | 377 | 0.060 |
Why?
| | Blood Pressure | 1 | 2008 | 537 | 0.060 |
Why?
| | Coronary Artery Disease | 1 | 2009 | 294 | 0.060 |
Why?
| | Two-Hybrid System Techniques | 1 | 2004 | 23 | 0.060 |
Why?
| | Atrial Natriuretic Factor | 1 | 2004 | 25 | 0.060 |
Why?
| | Patient Compliance | 1 | 2006 | 230 | 0.060 |
Why?
| | Blotting, Northern | 1 | 2004 | 106 | 0.060 |
Why?
| | Immunoprecipitation | 1 | 2004 | 57 | 0.060 |
Why?
| | DNA, Complementary | 1 | 2004 | 135 | 0.060 |
Why?
| | Sequence Homology, Amino Acid | 1 | 2004 | 140 | 0.060 |
Why?
| | Transcriptional Activation | 1 | 2004 | 122 | 0.060 |
Why?
| | Proportional Hazards Models | 3 | 2014 | 443 | 0.060 |
Why?
| | Plasmids | 1 | 2004 | 163 | 0.060 |
Why?
| | Leukocytes, Mononuclear | 2 | 2016 | 123 | 0.060 |
Why?
| | Antineoplastic Agents | 1 | 2012 | 1222 | 0.060 |
Why?
| | Homeodomain Proteins | 1 | 2004 | 80 | 0.060 |
Why?
| | Glutathione Transferase | 1 | 2004 | 174 | 0.050 |
Why?
| | Microscopy, Fluorescence | 1 | 2004 | 160 | 0.050 |
Why?
| | Cardiomyopathies | 1 | 2004 | 121 | 0.050 |
Why?
| | Echocardiography, Doppler | 1 | 2003 | 57 | 0.050 |
Why?
| | Tomography, Emission-Computed, Single-Photon | 1 | 2023 | 52 | 0.050 |
Why?
| | Models, Animal | 1 | 2003 | 234 | 0.050 |
Why?
| | Proto-Oncogene Proteins c-bcl-2 | 1 | 2003 | 129 | 0.050 |
Why?
| | Ventricular Dysfunction, Left | 1 | 2003 | 108 | 0.050 |
Why?
| | Aggression | 1 | 2002 | 50 | 0.050 |
Why?
| | Dopamine | 1 | 2023 | 173 | 0.050 |
Why?
| | Point Mutation | 1 | 2002 | 67 | 0.050 |
Why?
| | Drug Administration Schedule | 1 | 2002 | 374 | 0.050 |
Why?
| | Disease Models, Animal | 1 | 2006 | 1478 | 0.050 |
Why?
| | Risk Factors | 3 | 2018 | 3889 | 0.050 |
Why?
| | Carcinoma, Non-Small-Cell Lung | 1 | 2003 | 170 | 0.040 |
Why?
| | Psychiatric Status Rating Scales | 1 | 2002 | 323 | 0.040 |
Why?
| | DNA, Mitochondrial | 1 | 2002 | 114 | 0.040 |
Why?
| | Positron-Emission Tomography | 1 | 2023 | 301 | 0.040 |
Why?
| | Cross-Sectional Studies | 1 | 2006 | 1678 | 0.040 |
Why?
| | Geriatric Assessment | 1 | 2021 | 117 | 0.040 |
Why?
| | National Institute on Aging (U.S.) | 1 | 2019 | 1 | 0.040 |
Why?
| | Europe | 1 | 2019 | 87 | 0.040 |
Why?
| | Qualitative Research | 1 | 2021 | 364 | 0.040 |
Why?
| | Beverages | 1 | 2019 | 57 | 0.040 |
Why?
| | Severity of Illness Index | 1 | 2002 | 1026 | 0.040 |
Why?
| | Meals | 1 | 2019 | 63 | 0.040 |
Why?
| | Myocardial Infarction | 2 | 2014 | 412 | 0.040 |
Why?
| | Registries | 2 | 2013 | 581 | 0.040 |
Why?
| | Matrix Metalloproteinases | 1 | 2017 | 47 | 0.040 |
Why?
| | Lung Neoplasms | 1 | 2003 | 636 | 0.030 |
Why?
| | Blood-Brain Barrier | 1 | 2016 | 48 | 0.030 |
Why?
| | Polymorphism, Genetic | 1 | 2017 | 185 | 0.030 |
Why?
| | Gene Regulatory Networks | 1 | 2017 | 111 | 0.030 |
Why?
| | Arginine | 1 | 2017 | 182 | 0.030 |
Why?
| | Angiotensin II | 1 | 2016 | 162 | 0.030 |
Why?
| | Pilot Projects | 1 | 2017 | 721 | 0.030 |
Why?
| | Analysis of Variance | 1 | 2016 | 554 | 0.030 |
Why?
| | Myocardial Revascularization | 1 | 2014 | 21 | 0.030 |
Why?
| | Intubation, Gastrointestinal | 1 | 2014 | 28 | 0.030 |
Why?
| | Mice, Knockout | 1 | 2016 | 879 | 0.030 |
Why?
| | Health Surveys | 1 | 2014 | 238 | 0.030 |
Why?
| | Acute Disease | 1 | 2014 | 373 | 0.030 |
Why?
| | Cohort Studies | 1 | 2018 | 1542 | 0.030 |
Why?
| | Molecular Sequence Annotation | 1 | 2012 | 28 | 0.030 |
Why?
| | Lymphopenia | 1 | 2012 | 18 | 0.030 |
Why?
| | Tunicamycin | 1 | 2012 | 11 | 0.020 |
Why?
| | Thapsigargin | 1 | 2012 | 8 | 0.020 |
Why?
| | Palmitic Acid | 1 | 2012 | 22 | 0.020 |
Why?
| | Sex Factors | 1 | 2014 | 727 | 0.020 |
Why?
| | Socioeconomic Factors | 1 | 2014 | 610 | 0.020 |
Why?
| | Thrombocytopenia | 1 | 2012 | 89 | 0.020 |
Why?
| | Predictive Value of Tests | 1 | 2014 | 944 | 0.020 |
Why?
| | Cognition | 1 | 2014 | 331 | 0.020 |
Why?
| | Stents | 1 | 2014 | 351 | 0.020 |
Why?
| | RNA | 1 | 2012 | 168 | 0.020 |
Why?
| | Stem Cells | 1 | 2012 | 177 | 0.020 |
Why?
| | Phosphorylation | 1 | 2012 | 528 | 0.020 |
Why?
| | Survival Rate | 1 | 2013 | 945 | 0.020 |
Why?
| | Liver | 1 | 2016 | 1156 | 0.020 |
Why?
| | Brazil | 1 | 2010 | 38 | 0.020 |
Why?
| | Multicenter Studies as Topic | 1 | 2009 | 105 | 0.020 |
Why?
| | Body Mass Index | 1 | 2012 | 689 | 0.020 |
Why?
| | Safety | 1 | 2009 | 79 | 0.020 |
Why?
| | Vocabulary | 1 | 2008 | 13 | 0.020 |
Why?
| | Perceptual Masking | 1 | 2008 | 11 | 0.020 |
Why?
| | Evidence-Based Medicine | 1 | 2009 | 261 | 0.020 |
Why?
| | Kaplan-Meier Estimate | 1 | 2009 | 483 | 0.020 |
Why?
| | Patient Selection | 1 | 2009 | 259 | 0.020 |
Why?
| | Administration, Oral | 1 | 2009 | 451 | 0.020 |
Why?
| | Attitude | 1 | 2008 | 70 | 0.020 |
Why?
| | Body Composition | 1 | 2009 | 338 | 0.020 |
Why?
| | Young Adult | 1 | 2016 | 4329 | 0.020 |
Why?
| | Thrombosis | 1 | 2009 | 253 | 0.020 |
Why?
| | Randomized Controlled Trials as Topic | 1 | 2009 | 595 | 0.020 |
Why?
| | Genetic Engineering | 1 | 2005 | 23 | 0.020 |
Why?
| | Research | 1 | 2005 | 107 | 0.010 |
Why?
| | Adolescent | 1 | 2016 | 6739 | 0.010 |
Why?
| | Health Policy | 1 | 2005 | 158 | 0.010 |
Why?
| | Risk Assessment | 1 | 2009 | 1327 | 0.010 |
Why?
| | Cheek | 1 | 2002 | 9 | 0.010 |
Why?
| | Mouth Mucosa | 1 | 2002 | 23 | 0.010 |
Why?
| | Mitosis | 1 | 2002 | 88 | 0.010 |
Why?
| | Cell Division | 1 | 2002 | 291 | 0.010 |
Why?
| | Sequence Analysis, DNA | 1 | 2002 | 229 | 0.010 |
Why?
| | Gene Deletion | 1 | 2002 | 272 | 0.010 |
Why?
| | Polymerase Chain Reaction | 1 | 2002 | 461 | 0.010 |
Why?
| | Epithelial Cells | 1 | 2002 | 215 | 0.010 |
Why?
| | Prognosis | 1 | 2003 | 2099 | 0.010 |
Why?
| | Mutation | 1 | 2002 | 1347 | 0.010 |
Why?
| | Infant | 1 | 2002 | 3733 | 0.010 |
Why?
| | Child, Preschool | 1 | 2002 | 4076 | 0.010 |
Why?
| | Neoplasms | 1 | 2002 | 1325 | 0.010 |
Why?
| | Child | 1 | 2002 | 7248 | 0.000 |
Why?
|
|
Wei's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically based on a person's publications. Keywords from attributed publications are matched to keywords from the MeSH. _
Co-Authors  People in Profiles who have published with this person. _
Similar People  People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
|